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damage was studied by fluorescence-based quantitative 
PCR in 84 transgenic and 93 wild-type samples.  Results: A 
clear pattern of decrease in mtDNA copy number with age 
and accumulation of 3,867-bp deletions at the initial stages 
(both being more pronounced in transgenic mice) was ob-
served. Pontine nuclei, the affected tissue in transgenic mice, 
displayed 1.5 times less copies of mtDNA than nonaffected 
brain tissue hippocampus (odds ratio = 1.21). Pontine nuclei 
displayed the highest percentage of mtDNA deletions (6.05% 
more in transgenic mice).  Conclusion: These results suggest 
that mtDNA damage is related to the initiation of the pheno-
type in transgenic mice; mtDNA 3,867-bp deletions may be 
a biomarker of the initial stages of the disease. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Machado-Joseph disease (MJD/SCA3; MIM 109150) is 
a late-onset progressive neurological disorder, considered 
the most common autosomal dominant spinocerebellar 
ataxia worldwide  [1, 2] , reaching its highest prevalence in 
the Azores Islands (Portugal) (1/239 in the island of 
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 Abstract 
 Background: Machado-Joseph disease (MJD) is an autoso-
mal dominant spinocerebellar ataxia caused by a CAG tract 
expansions in the  ATXN3 gene. Patterns of mitochondrial 
damage associated with pathological findings of brain tis-
sues could provide molecular biomarkers of this disorder. 
 Objective: The potential of mitochondrial DNA (mtDNA) 
damage as a biomarker of MJD progression was investigated 
using a transgenic mouse model.  Methods: DNA was ob-
tained from affected (pontine nuclei) and nonaffected tis-
sues (hippocampus and blood) of transgenic animals of 
three distinct age groups: 8 weeks, before onset of the phe-
notype; 16 weeks, at onset, and 24 weeks, at well-established 
phenotype. Wild-type littermate mice, serving as controls, 
were analyzed for the same tissues and age groups. mtDNA 
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Flores, according to Bettencourt et al.  [3] ). Most MJD pa-
tients show the first symptoms in adulthood (mean age 
about 40 years), but onset extremes at 4 and 70 years have 
been described  [4, 5] . The MJD phenotype is complex and 
pleomorphic, involving the cerebellar, ocular motor, py-
ramidal, extrapyramidal and peripheral motor systems 
to variable degrees  [5] .
 The  ATXN3 gene (MIM 607047), the causative gene of 
MJD, spans a genomic region of 48 kb, and contains a 
(CAG)n repeat tract encoding for glutamine repeats at 
exon 10  [6, 7] . Wild-type alleles have 12–44 CAG repeats 
while, consensually, the mutant alleles contain from 61 to 
87 CAG repeats  [8] . The size of the (CAG)n tract in the 
expanded alleles negatively correlates with the age at on-
set  [9] . The  ATXN3 gene encodes for ataxin-3, which, in 
its mutated form, presents an elongation of a polygluta-
mine (poly-Q) tract near its C-terminus  [10] . Despite the 
ubiquitous expression of ataxin-3 in brain and nonbrain 
tissues, selective neuronal cell death has been reported 
[e.g. ref.  11, 12 ]. Neuropathological studies typically re-
veal neuronal loss in the cerebellar dentate nucleus, pons, 
substantia nigra, thalamus, globus pallidus, anterior 
horn cells and Clarke’s column in the spinal cord, ves-
tibular nucleus, many cranial motor nuclei as well as oth-
er brainstem nuclei  [12] . The mechanisms by which mu-
tant ataxin-3 induces neurodegeneration have been ex-
tensively studied but remain incompletely understood 
[reviewed in ref.  13 ]. Difficulties in fully understanding 
the pathogenic process leading to the neurotoxicity of 
mutant ataxin-3 are reflected in the current lack of spe-
cific strategies to reverse morbidity. Several clinical trials 
using drugs that aim to delay disease progression are on-
going. A crucial aspect, which may compromise the suc-
cess of clinical trials in MJD, is the lack of measurement 
tools to monitor disease progression and detect subtle 
therapeutic benefits. Molecular biomarkers of progres-
sion are therefore urgently needed in this disorder.
 Morphological, biochemical, genetic as well as cell and 
animal model studies reveal that mitochondrial damage 
is an important factor in aging and age-related neurode-
generation  [14] . Mitochondria are known to play a piv-
otal role in many metabolic and apoptotic pathways that 
regulate cellular life and death. Mitochondrial DNA 
(mtDNA) alterations, including quantitative and qualita-
tive changes, have been reported in several neurodegen-
erative disorders. In poly-Q disorders, namely in Hun-
tington’s disease, the accumulation of large deletions in 
mtDNA has been described  [15] . Although mtDNA dam-
age in MJD has already been reported in the literature  [16, 
17] , including depletion and deletion, in peripheral cells 
of patients and in cellular models of the disease, no inves-
tigations on the association between neuropathological 
findings and patterns of mtDNA damage have been per-
formed so far due to difficulties in obtaining brain tis-
sues. To overcome those difficulties, we used a transgen-
ic mouse model of MJD (CMVMJD94) in the present 
study, which expresses the full-length human ataxin-3 
and displays a motor phenotype in the absence of evident 
cell death  [18] . The main goal was to investigate the rela-
tionship between damage to mtDNA (copy number de-
pletion, as well as the accumulation of deletions), and the 
initiation and progression of the transgenic mouse phe-
notype. Our aims were: (a) to identify a pattern of mtD-
NA damage in affected brain tissue as well as nonaffected 
(brain and nonbrain) tissues associated with the develop-
ment of the phenotype; (b) to define the effect of aging on 
the accumulation of mtDNA damage, and its tissue spec-
ificity. To fulfill these objectives, mtDNA copy number 
in distinct tissues of the transgenic mice (brain and non-
brain/affected and nonaffected) and at different stages 
relatively to the onset of the phenotype, was determined 
and compared with values obtained in controls. The pres-
ence of the mtDNA 3,867-bp deletion, the homolog of the 
human mtDNA 4977-bp deletion, considered as a marker 
of aging, was also quantified and compared with values 
obtained in controls.
 Materials and Methods 
 Mouse Model and Experimental Design 
 A novel cDNA transgenic mouse model of the early stages of 
MJD ( Mus musculus , strain C57B1/6, line CMVMJD94) devel-
oped by P. Maciel’s group was used in the present study  [18] . These 
transgenic mice ubiquitously express the full-length mutant hu-
man ataxin-3, under the regulation of the cytomegalovirus pro-
moter, and display a motor phenotype. The mouse model used 
also mimics some key features that are common in MJD patients, 
namely CAG repeat instability, neurological damage and brain 
pathology. Therefore, it has been proposed as a useful model for 
dissecting the initial cellular and molecular events in the patho-
genesis of MJD  [18] . DNA from 28 transgenic mice carrying the 
expanded repeat (98–104 CAGs) (cases) was compared with DNA 
from 31 wild-type littermate mice (C57Bl/6 strain), matched by 
sex and age (controls). Unaffected brain tissue (hippocampus) 
and affected brain tissue (pontine nuclei), as well as a nonbrain 
tissue (blood) were collected from transgenic mice. These three 
tissues were obtained from each animal and were analyzed with-
in three age groups defined as follows: 8-week-old, corresponding 
to the age prior to the appearance of the phenotype; 16-week-old, 
corresponding to the age at onset; 24-week-old, corresponding to 
the age at which the phenotype is well established. The same tis-
sues of mice of the same age groups were studied in control ani-
mals (8–11 animals analyzed per group).
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 The animals were maintained in accordance with European 
regulations (European Union Directive 86/609/EEC). Animal fa-
cilities and the people directly involved in animal experiments 
were certified by the Portuguese regulatory entity – Directorate 
General for Veterinary Medicine. All protocols were approved by 
the joint Animal Ethics Committee of the Life and Health Sci-
ences Research Institute, University of Minho, and the Institute 
for Molecular and Cell Biology, University of Porto, Porto, Portu-
gal.
 DNA Isolation and Molecular Analysis of the (CAG)n Repeats 
 DNA was extracted from tail biopsies (blood) or from macro-
dissected brain tissues (hippocampus and pontine nuclei) using 
the Puregene DNA isolation kit (Gentra Systems, Minneapolis, 
Minn., USA), and the size of the CAG tract was assessed as previ-
ously described  [18] .
 Quantitative Real-Time PCR 
 Determination of the mtDNA copy number and quantitative 
detection of the mtDNA 3867-bp deletion were performed by flu-
orescence-based quantitative real-time PCR using the Applied 
Biosystems 7900HT real-time PCR System (Applied Biosystems, 
Foster City, Calif., USA). mtDNA quantity was corrected by si-
multaneous measurement of a nuclear  Gapdh gene (TaqMan Ro-
dent  Gapdh Control, P/N 4308313, Applied Biosystems; the 
nDNA-specific fluorescent probe was labeled internally using 
VIC fluorescent dye) by the ‘absolute quantitation’ (standard 
curve) method. Primers and TaqMan MGB probes (minor groove 
binder, labeled at the 5  -end with a fluorescent reporter, 6-FAM) 
were designed for the sequence outside the deletion-specific re-
gion (mtDNA ALL ; mtDNA copy number measurement) and in-
side the deletion-specific region (mtDNA NORMAL ; detection of
the mtDNA 3,867-bp deletion) using Primer Express v3.0 (Ap-
plied Biosystems). The primers used were: mtDNA ALL (5  -3  ) for-
ward – TCGCCACTTCTATAACAGCTATG, reverse – AATGC-
TAGGCGTTTGATTGG, probe mtDNA ALL (6-FAM MGBNFQ) 
GCAGACGAACAAGACATC; primers mtDNA NORMAL (5  -3  ) 
forward – TGTACCCACGCATTCTTCAA, reverse – AATG-
CTAGGCGTTTGATTGG, probe mtDNA NORMAL (6-FAM
MGBNFQ) ACGAAAATGACCCAGACCTC. Primer sequences 
were screened by BLASTn to eliminate any homology to human 
DNA and mouse nuclear DNA and were also screened against the 
NCBI SNP database. A total volume of 20   l was used in PCRs 
containing: 20 ng of template DNA, 5 pmol of each primer and 
probe, 10 ! buffer, 1.5 units of BioTaq DNA polymerase (Bioline), 
1.25 m M MgCl 2 , 0.2 m M dNTPs and 1   l of TaqMan Rodent  Gap-
dh Control. The thermal cycling conditions were as follows: 95  °  C 
for 10 min, followed by 40 cycles of 95   °  C for 15 s, and 59  °  C for 1 
min. Every sample was tested in triplicate. In each PCR run, se-
rial dilutions of the mouse genomic DNA with known amounts 
of input nuclear copy number were included to create a standard 
reference curve. The absolute mtDNA copy number (mtDNA ALL ) 
was calculated as described in the manual  Creating Standard 
Curves with Genomic DNA or Plasmid DNA Templates for Use in 
Quantitative PCR by Applied Biosystems (www6.appliedbiosys-
tems.com/support/tutorials/pdf/quant_pcr.pdf). The number of 
mtDNA copies with deletions was calculated by the difference of 
total mtDNA copies (mtDNA ALL ) and mtDNA copies without de-
letions (mtDNA NORMAL ).
 Statistical Analysis 
 Copy Number Macro (Applied Biosystems) and SDS soft-
ware, version 2.X, were used to process the data. The amount of 
mtDNA per cell was calculated and the results are expressed as 
mean copy number for three fluorescence-based quantitative re-
al-time PCRs. Statistical analysis was performed using Statistica 
software package, version 7.0  [19] . A p value less than 0.05 was 
considered statistically significant. Odds ratios (ORs) were cal-
culated from the data presented in  figure 1 . Statistical association 
between variables was assessed by multiple regression analysis. 
Total mtDNA copy number and percentage of mtDNA copies 
with deletions were used as dependent variables. Age, mtDNA 
origin (tissue), sample origin (wild type or transgenic) and num-
ber of CAG repeats were used as predictors in multiple regression 
analysis. Multiple regression analysis was performed for: (a) all 
samples with sample origin (wild type or transgenic) and number 
of CAG repeats as predictors; (b) transgenic samples with age, 
mtDNA origin (tissue) and number of CAG repeats as predictors, 
and (c) wild-type samples with age and tissue as predictors. In 
multiple regression analysis,   -coefficients were calculated to 
measure the individual contribution of each predictor. The sig-
nificance of the contribution of a predictor is described by the t 
and p values (the smaller the p value and the larger the t value, 
the greater the contribution of a particular predictor). The cumu-
lative contribution of predictors is described by multiple correla-
tion coefficients (r). r 2 values show how much of the variability in 
the outcome is accounted for by the predictors. Adjusted r 2 values 
give an idea how the model generalizes, the closer the values, the 
better the model. The F ratio from the ANOVA analysis repre-
sents the ratio of the improvement in prediction that results from 
fitting the model relative to the inaccuracy that still exists in the 
model (‘residual’).
 The mean values of one group of variables were compared with 
the mean of another group using Fisher’s least significant differ-
ence test.
 Results 
 Findings in Wild-Type Animals 
 Results revealed that the total mtDNA copy number 
of older mice was reduced when compared with that of 
younger mice, thus indicating the effect of aging on the 
accumulation of mtDNA depletions (p  ! 0.001,  table 1 , 
model B). A 1.59-fold decrease in total mtDNA copy 
number from week 8 to week 24 was observed. The 
mean percentage of mtDNA copies with deletions 
reached its maximum in 8-week-old mice (up to 58% in 
pontine nuclei) ( fig 1 ,  2 c), again decreasing with age ( ta-
ble 1 ).
 Among brain tissues, pontine nuclei had a lower mean 
mtDNA copy number ( fig. 2 b). Additionally, the highest 
mean level of mtDNA deletions was also observed in pon-
tine nuclei ( fig. 1 ,  2 d).
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 Fig. 1. Mean mtDNA copy number and percentage of mtDNA copies with deletions in different tissues and ages 
of transgenic and wild-type mice. Hp = Hippocampus; Pn = pontine nuclei; Bl = blood; bars on the diagram 
represent standard deviation; numbers above/at the bars represent actual value of mean mtDNA copy number 
or percentage of mtDNA copies with deletions; mean value for each tissue represents the mean value for weeks 
8, 16 and 24. 
Table 1.  Parameters estimates of multiple regression models
mtDNA copy number mtDNA copies with deletions, %
 95% CI p value t value  95% CI p value t value
Model A
Sample origin1 –0.75 –6.82 to 5.31 0.81 –0.25 –9.25 –15.14 to –3.36 <0.001 –3.10
(CAG)n –0.69 –6.75 to 5.37 0.82 –0.23 –9.16 –15.05 to –3.27 <0.001 –3.07
Model B
Age –0.41 –0.61 to –0.22 <0.001 –4.17 –0.54 –0.71 to –0.36 <0.001 –6.16
Tissue –0.24 –0.47 to –0.01 0.04 –2.11 0.01 –0.19 to 0.21 0.92 0.10
(CAG)n –0.74 –7.44 to 5.96 0.83 –0.22 –10.80 –16.67 to –4.93 <0.001 –3.66
Model C
Age –0.15 –0.31 to 0.00 0.047 –2.01 –0.58 –0.75 to –0.41 <0.001 –6.88
Tissue –0.66 –0.81 to –0.51 <0.001 –8.60 –0.11 –0.28 to 0.06 0.20 –1.28
Mul tiple regression analysis was performed to find out how 
mtDNA copy number and percentage of mtDNA copies with dele-
tions (used as dependent variables) of the samples analyzed are 
affected by other variables (predictors), such as age, mtDNA ori-
gin (tissue) and (CAG)n. Three models were analyzed, which dif-
fered in predictors and sample origin (transgenic or wild type).
Model A: mtDNA copy number and percentage of mtDNA 
copies with deletions (dependent variables) versus sample origin 
(transgenic or wild type) and (CAG)n (predictors), all samples.
Model B: mtDNA copy number and percentage of mtDNA 
copies with deletions (dependent variables) versus age, mtDNA 
origin (tissue) and (CAG)n (predictors), transgenic samples.
Model C: mtDNA copy number and percentage of mtDNA 
copies with deletions (dependent variables) versus age and
mtDNA origin (tissue) (predictors), wild-type samples. 
1 Transgenic or wild type;  = -coefficient; 95% CI = confi-
dence interval at 95% confidence level.
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 Wild-Type versus Transgenic Animals 
 Decrease in mtDNA Copy Number with Age 
 Compared to wild-type mice, transgenic animals 
demonstrated more evident accumulation of mtDNA de-
pletion with age (r 2 = 0.088, p = 0.006 vs. r 2 = 0.073, p = 
0.009 in wild-type mice,  fig. 1 ,  2 a, online suppl. table 1; 
see www.karger.com/doi/10.1159/000339207 for all on-
line suppl. material). The mean decrease in mtDNA copy 
number with age in all tissues was 1.22 times higher in 
transgenic animals (OR for hippocampus = 1.02, OR for 
pontine nuclei = 1.17, and OR for blood = 1.48). Compar-
ison of mtDNA copy number in all tissues of transgenic 
mice between the initial stage of the disease (presymp-
tomatic versus onset, 8–16 weeks) and the later stage of 
the disease (onset versus well-established phenotype, 16–
24 weeks) showed a higher difference for the initial stage 
of the disease (OR = 1.24–2.21). While in wild-type mice, 
a decrease in mtDNA copy number between 8–16 versus 
16–24 weeks was observed only in blood and the hippo-
campus (OR = 1.09 and 1.24, respectively; OR = 0.92 for 
blood), but, once again, this difference was more evident 
in transgenic mice (OR = 1.33 for the hippocampus, and 
OR = 2.03 for blood). Concerning the pontine nuclei, this 
difference was also more evident in transgenic mice
(OR = 1.55).
 Accumulation of mtDNA Deletions at the Initial 
Stage of the Disease 
 Compared to wild-type mice, transgenic animals dem-
onstrated more evident accumulation of deletions (up to 
72.75% in the pontine nuclei of transgenic vs. 58% of wild-
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 Fig. 2. Correlation of mtDNA copy number and percentage of mtDNA copies with deletions with age and
mtDNA origin (tissue).  a mtDNA copy number versus age.  b mtDNA copy number versus tissue.  c Percentage 
of mtDNA copies with deletions versus age.  d Percentage of mtDNA copies with deletions versus tissue. 
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type animals) ( fig. 1 ; p  ! 0.001, r 2 = 0.37 and 0.27 for trans-
genic and wild type, respectively;  fig. 2 c). Samples of al-
most all tissues of transgenic mice had a much higher mean 
percentage of mtDNA copies with deletions compared to 
wild-type mice. The difference in mean percentage of 
mtDNA copies with deletions between transgenic and 
wild-type mice ranged from 1.1% (pontine  nuclei, 24 
weeks) to 14.75% (pontine nuclei, 8 weeks)  (calculated from 
 fig. 1 ). Multiple regression analysis demonstrated that the 
percentage of mtDNA deletions is significantly influenced 
by sample origin (wild type or transgenic) ( table 1 , model 
A, p  ! 0.001). Brain tissues of transgenic mice and all tis-
sues of wild-type mice showed statistically significant dif-
ferences between mean deletion values for 8 versus 16 
weeks (corresponding to presymptomatic stage and onset 
in transgenic mice) as well as for 8 versus 24 weeks (corre-
sponding to presymptomatic stage and well-established 
phenotype in transgenic mice). For blood, a statistically 
significant difference in transgenic animals was found be-
tween the presymptomatic stage and well-established phe-
notype (8 vs. 24 weeks), as well as between onset and well-
established phenotype (16 vs. 24 weeks). On the other hand, 
when comparing transgenic with wild-type mice of the 
same age, significant differences between mean deletion 
values were observed for all tissues for 8 versus 16 weeks 
and 8 versus 24 weeks, with more pronounced changes in 
cells of transgenic mice (online suppl. table 2).
 More Evident Decrease in mtDNA Copy Number 
with Age and Highest Accumulation of mtDNA 
Deletions in Pontine Nuclei 
 The decrease in mtDNA copy number with age among 
brain tissues was more pronounced in pontine nuclei (the 
affected tissue in transgenic mice) (OR for the hippocam-
pus = 1.02, OR for pontine nuclei = 1.17). Pontine nuclei 
had a lower global mean mtDNA copy number compared 
with the hippocampus in both transgenic and wild-type 
mice (1.5 and 1.24 times less copies, respectively, OR = 
1.21). Mean accumulation of mtDNA deletions was also 
the highest in pontine nuclei (6.05% more in transgenic 
than in wild-type mice; 2.47% more than in the hippo-
campus and 10.82% more than in blood for transgenic 
mice;  fig. 1 ). Both results demonstrate that thte pontine 
nuclei were likely to have more mtDNA damage than the 
hippocampus and blood (affected vs. nonaffected tissues 
in transgenic mice).
 Findings in Blood 
 In order to evaluate the application potential of the re-
sults obtained using brain tissues in the mouse model, in 
the context of biomarker identification, special attention 
was paid to mtDNA damage in blood, a biological mate-
rial whose collection is minimally invasive, rapid and ap-
propriate for multiple sampling. Findings of mtDNA 
damage in blood of transgenic animals were similar to 
those in affected tissue of pontine nuclei, namely a de-
crease in mtDNA copy number from week 8 to week 16 
and almost no changes or a slight increase from week 16 
to week 24, the highest percentage of mtDNA copies with 
deletions being observed in week 8, with a subsequent 
decrease ( fig. 1 ). Although, in contrast to other tissues, 
blood demonstrated higher percentages of mtDNA cop-
ies with deletions in wild-type mice compared with trans-
genic mice at 24 weeks, it followed a pattern of a promi-
nent decrease in the percentage of mtDNA copies with 
deletions from week 16 to week 24 in transgenic mice 
compared with a slight decrease in wild-type mice (22 vs. 
1.41%, OR = 15.6), which is characteristic for brain tis-
sues. And, importantly, at week 16, which corresponds to 
the onset in transgenic mice, the percentage of mtDNA 
copies with deletions in blood was much higher in trans-
genic mice (13.59%).
 Global Analysis 
 A large part of the variation in mtDNA copy number 
and percentage of mtDNA copies with deletions was ac-
counted for by age, mtDNA origin (tissue) and number of 
CAG repeats (for transgenic mice). In transgenic mice, 
these variables had a higher impact on the percentage of 
mtDNA copies with deletions (40.7% of the variation, p  ! 
0.001.  Table 2 , model B) while in wild-type mice, the im-
pact was higher on total mtDNA copy number (47.3% of 
the variation, p  ! 0.001;  table 1 ,  2 , model C).
 The above-mentioned results indicate a clear differ-
ence between transgenic and wild-type mice, which is ex-
pressed as more evident accumulation of mtDNA deple-
tion with age, starting from week 8 (OR up to 1.48 for 
transgenic vs. wild-type mice), and more evident accu-
mulation of mtDNA deletions (up to 72.75 vs. 58% of 
wild-type animals) in most tissues of transgenic animals. 
Several key traits in mtDNA dynamics can be highlight-
ed: decrease in mtDNA copy number with age, accumu-
lation of deletions at the initial stages (both more pro-
nounced in transgenic mice). A more evident decrease in 
mtDNA copy number with age (comparing brain tissues), 
and the highest accumulation of mtDNA deletions (com-
paring all tissues) was observed in the affected tissue. 
Most tissues demonstrated a decline in mtDNA copy 
number (except pontine nuclei and blood in 16- to 
24-week-old transgenic mice, and pontine nuclei in 8- to 
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16-week-old wild-type mice) and an unexpected decline 
in the percentage of mtDNA copies with deletions (except 
for the hippocampus in 8- to 16-week-old wild-type mice) 
with age ( fig. 1 ,  2 ). Blood showed the lowest values for 
both mtDNA copy number and percentage of mtDNA 
copies with deletions, but demonstrated a pattern of 
mtDNA damage similar to that of pontine nuclei in trans-
genic animals. The affected tissue had lower mtDNA 
copy numbers in comparison with nonaffected brain tis-
sue, and the highest percentage of mtDNA copies with 
deletions among all tissues ( fig. 1 ).
 Discussion 
 Previous studies have shown that mtDNA alterations 
could play a role in the pathogenesis of poly-Q diseases 
 [14, 16, 17, 20, 21] . For MJD, the evidence concerning 
mtDNA alterations is scarce. Liu et al.  [16] , for instance, 
demonstrated that leukocytes of patients present signifi-
cant mtDNA depletions compared with healthy controls. 
These authors, however, did not take into account the age 
at disease onset and the time of disease progression: this 
severely limits the analysis since, for example, they were 
not able to take into account the time elapsed since onset, 
which is crucial, considering that disease-associated 
mtDNA damage may depend on disease progression it-
self. Moreover, no investigations on the association be-
tween neuropathological findings and patterns of dam-
age have been performed so far, due to difficulties in ob-
taining brain tissues. Using stably transfected cells with 
78 CAGs, Yu et al.  [17] demonstrated that the mtDNA 
copy number in such cells was lower than that of wild-
type lines. This trend for depletion was also observed for 
mtDNA obtained from leukocytes of MJD patients; fur-
thermore the frequency of the 4977-bp deletion was high-
er than in the matching healthy controls, an indication of 
higher damage in the mtDNA molecules of patients. 
Again, in this work, the lack of phenotypic data and the 
reduced number of cases precludes any conclusions as to 
the interplay between mtDNA damage and the evolution 
of the disease. Although not conclusive, due to the limita-
tions referred to, previous research conducted on mtDNA 
damage and MJD led us to consider the possibility that 
there is a pattern of mitochondrial alterations associated 
with disease progression. Thus, the novelty of our study 
resided in the use of a mouse model and in comparing 
distinct tissues (affected and nonaffected) and different 
stages relatively to the onset of the phenotype, allowing 
us to draw some conclusions concerning the relationship 
between the evolution of the disease and the pattern of 
damage in affected and nonaffected tissues.
 In this study, we analyzed in vivo how changes in 
mtDNA copy number and the accumulation of mtDNA 
deletions were related to the MJD transgenic mouse phe-
notype and its progression at the early stages of the dis-
ease. A more pronounced decrease in mtDNA copy num-
ber with age and accumulation of deletions at the initial 
Table 2.  Summary of multiple regression models (mtDNA copy number and percentage of mtDNA copies with deletions versus age, 
mtDNA origin (tissue) and (CAG)n)
Multiple r Multiple r2 Adjusted r2 F value p value
Model A
mtDNA copy number 0.065 0.004 –0.007 0.372 0.690
mtDNA copies with deletions, % 0.246 0.060 0.050 5.588 0.004
Model B
mtDNA copy number 0.476 0.226 0.187 5.777 <0.001
mtDNA copies with deletions, % 0.638 0.407 0.377 13.546 <0.001
Model C
mtDNA copy number 0.688 0.473 0.462 40.469 <0.001
mtDNA copies with deletions, % 0.600 0.360 0.345 25.263 <0.001
Model A: mtDNA copy number and percentage of mtDNA 
copies with deletions (dependent variables) versus sample origin 
(transgenic or wild type) and (CAG)n (predictors), all samples.
Model B: mtDNA copy number and percentage of mtDNA 
copies with deletions (dependent variables) versus age, mtDNA 
origin (tissue) and (CAG)n (predictors), transgenic samples.
Model C: mtDNA copy number and percentage of mtDNA 
copies with deletions (dependent variables) versus age and
mtDNA origin (tissue) (predictors), wild-type samples. 
r = Multiple correlation coefficient; r2 = squared multiple cor-
relation coefficient.
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stage of the disease were observed in transgenic mice. 
Among brain tissues, a more evident decrease in mtDNA 
copy number with age was observed in pontine nuclei, 
the affected brain region. Accumulation of mtDNA dele-
tions was, furthermore, also highest in the affected tissue. 
Consistent with the findings of previous research  [16, 17] , 
aging was shown to be associated with mtDNA depletion; 
within brain tissues, this depletion was more pronounced 
in the affected tissue (pontine nuclei) of transgenic mice 
compared to wild-type animals. Although not reaching 
statistical significance for some groups, age and tissue 
were found to have a significant impact on mtDNA copy 
number, as evidenced by multiple regression analysis. 
The lack of significance in some of the groups may be due 
to the small sample size (n = 8–11) or quite high level of 
the standard deviations in the groups. The difference in 
mtDNA copy number at the initial stages of the disease 
was found to be higher than at later stages, and it was up 
to twice as high in transgenic animals compared to wild-
type animals of the same age groups. Thus, the progres-
sive depletion associated with aging is more evident in 
transgenic mice. This pattern was more evident in pon-
tine nuclei (when comparing brain tissues). Globally, the 
results obtained indicate that mtDNA damage could be 
related to the initiation of the phenotype in this MJD 
transgenic mouse model.
 The mtDNA 3,867-bp deletion causes removal or 
truncation of six structural (ATPase 6/8, COIII, ND3, 
ND4L, and ND4) and five tRNA genes. In contrast to 
previous observations  [15, 17] , which are consistent with 
expectations of higher rates of mtDNA deletion at the 
late stages of the disease, we observed that the mtDNA 
3,867-bp deletion was more likely to be present in young-
er transgenic mice, in accordance with the recent results 
of Chen et al.  [22] . However, compared to wild-type 
mice, transgenic mice in general demonstrated higher 
percentages of mtDNA copies with deletions, support-
ing the previous findings in healthy and affected MJD 
individuals  [17] . A possible explanation for the accumu-
lation of  mtDNA deletions at earlier ages could be that 
the cells, which are still alive at later ages, are the ones 
without the high percentage of deletion, while those with 
the deletion die, resulting in a lower percentage of dele-
tions at later ages. Among the tissues analyzed, the high-
est numbers of mtDNA deletions were observed in the 
affected tissue, the pontine nuclei. We speculate that the 
pontine nuclei may be particularly sensitive to damage 
and that the MJD-causing mutation affects pontine nu-
clei cells by changing their stress response. As a result, 
the antioxidant activity of cells is reduced, leading to an 
increase in the generation of reactive oxygen species and 
the ensuing mitochondrial damage, which in turn re-
sults in stress-induced apoptosis during the progression 
of MJD.
 Our results seem to support a possible higher oxidative 
injury in cells with mutant  ATXN3 because a decrease in 
mtDNA copy number with age and accumulation of dele-
tions (especially at the initial stages) were more evident in 
transgenic mice. We can thus hypothesize that the rela-
tive number of mtDNA 3,867-bp deletions is related to the 
stage of the disease.
 Based on the findings made in this study, we can sug-
gest that mtDNA damage has a potential to be used as a 
biomarker of phenotype initiation in MJD. Further stud-
ies using other models and a large number of patient sam-
ples are needed to confirm these findings, particularly for 
accessible tissues such as blood, and could represent a 
powerful tool in the context of drug trials.
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